Your session is about to expire
← Back to Search
Virus Therapy
Ebola Vaccine Immunology
Phase 2
Waitlist Available
Led By Nadine Rouphael, MD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 29, day 366
Awards & highlights
Study Summary
This trial will test an Ebola vaccine on 30 healthy adults. Blood & tissue samples will be taken before & after to see how the body responds.
Who is the study for?
Healthy adults who can consent, agree to use contraception, minimize exposure of bodily fluids to others for at least 14 days post-vaccination, and avoid blood donation for 56 days. Excluded are those with acute or chronic diseases needing treatment, substance abuse issues, immunocompromising conditions or treatments within the past 6 months, pregnancy/breastfeeding women, known allergies to vaccine components.Check my eligibility
What is being tested?
The trial is testing a single dose of an Ebola vaccine (rVSV∆G-ZEBOV-GP) in 30 participants. It involves collecting blood samples and other biopsies before and after vaccination to study immune responses over time in different body tissues.See study design
What are the potential side effects?
Potential side effects aren't specified here but could include typical vaccine reactions such as soreness at injection site, fever, fatigue or allergic reactions. Since it's an investigational vaccine more unique side effects may be possible.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 29, day 366
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 29, day 366
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Ebola-specific Antibody Titers
Secondary outcome measures
Frequency of Adverse Events (AEs)
Frequency of Adverse Events Related to Bone Marrow Aspiration
Frequency of Adverse Events Related to Fine Needle Aspiration/Biopsy of Lymph Node
+4 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)Experimental Treatment1 Intervention
Healthy adults who are at no risk for exposure to Ebola Virus and are not prior recipients of an Ebola vaccine receive a single dose of recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP).
Find a Location
Who is running the clinical trial?
Emory UniversityLead Sponsor
1,638 Previous Clinical Trials
2,560,512 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,888 Previous Clinical Trials
5,055,053 Total Patients Enrolled
1 Trials studying Ebola
250 Patients Enrolled for Ebola
Washington University School of MedicineOTHER
1,935 Previous Clinical Trials
2,299,777 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there availability for potential participants in this research study?
"As per the data on clinicaltrials.gov, this medical investigation is not recruiting participants presently; it was initially posted in November 1st 2023 and updated most recently October 20th of that same year. Nevertheless, there are 100 other studies seeking volunteers at present."
Answered by AI
Has the Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP) achieved FDA clearance?
"Based on the available clinical evidence, our team at Power rated rVSV∆G-ZEBOV-GP's safety as a 2. As this is only Phase 2 trial, there are some data demonstrating its security but none proving efficacy."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger